Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
Autoimmune Encephalitis, Encephalitis
Determine the difference in the modified Rankin score at 16 weeks in participants with anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis treated with "first-line" immunomodulatory therapies provided as standard-of-care, and either inebilizumab (investigational agent) or placebo.
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
-
University of Alabama at Birmingham, Birmingham, Alabama, United States, 35233
St. Joseph Hospital and Medical Center Barrow Neurological Institute, Phoenix, Arizona, United States, 85013
UC Irvine, Orange, California, United States, 92868
UC Davis, Sacramento, California, United States, 95816
Yale University, New Haven, Connecticut, United States, 06510
Mayo Clinic Jacksonville, Jacksonville, Florida, United States, 32224
University of Miami, Miami, Florida, United States, 33136
Northwestern University Feinberg School of Medicine, Chicago, Illinois, United States, 60611
University of Iowa, Iowa City, Iowa, United States, 52242
Massachusetts General Hospital, Boston, Massachusetts, United States, 02114
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
12 Years to
ALL
No
University of Utah,
Stacey L Clardy, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Utah
2026-08-31